CPRX
Catalyst Pharmaceuticals Inc
31.50$
+0.0%
vs. previous close
Closing price · As of: Jul 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.9% | +13.8% | +37.6% | +9.2% | +9.3% | +10.3% | +6.7% | +6.9% | +8.2% | +5.2% | +3.7% | |
| – | -20.3% | +14.2% | +84.5% | +17.3% | +13.6% | +15.7% | +10.0% | +10.6% | +12.4% | +4.9% | +5.2% | |
| – | -32.3% | +13.8% | +125.5% | +21.0% | +17.7% | +17.0% | +12.2% | +12.4% | +5.7% | +2.8% | +6.6% | |
| – | -32.3% | +13.8% | +125.5% | +21.0% | +17.7% | +17.0% | +12.2% | +12.4% | +5.7% | +2.8% | +6.6% | |
| – | +12.3% | +11.7% | +13.0% | -5.5% | +1.7% | +12.4% | +10.3% | -8.2% | +61.0% | +20.1% | +2.4% | |
| – | -16.0% | +73.1% | +27.5% | -9.7% | +11.1% | -2.4% | +1.2% | -5.7% | +50.3% | +32.6% | -6.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -4.8% | +16.1% | -4.8% | -5.1% | -5.3% | -5.6% | -6.0% | -6.3% | -6.8% | +2.4% | -7.4% | |
| – | -5.7% | +27.2% | +3.7% | +14.6% | +13.7% | +11.4% | -7.4% | +1.1% | +13.3% | +16.1% | -11.6% | |
| – | +10.1% | +31.6% | +4.6% | +16.0% | +14.2% | +14.5% | -7.5% | +1.2% | +13.9% | +14.3% | -10.0% | |
| – | +2.3% | +2.2% | +2.2% | +2.1% | +2.1% | +2.3% | +2.0% | +2.2% | +2.1% | +2.1% | +2.1% | |
| – | +4.0% | +221.8% | -30.6% | -30.7% | +62.5% | +43.5% | -32.5% | -50.6% | +64.5% | +23.2% | -36.2% | |
| – | -7.1% | +11.3% | +44.7% | +8.4% | +8.6% | +10.1% | +9.2% | +7.8% | +7.5% | +3.7% | +6.1% | |
| – | -26.3% | +40.3% | +19.2% | +28.2% | +23.7% | +24.4% | +19.9% | +15.2% | +13.4% | +6.1% | +10.4% | |
| – | -6.3% | +6.7% | +8.5% | +1.0% | +0.6% | +0.7% | +0.5% | +0.5% | -0.4% | +0.1% | -0.3% |
Data as of: July 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.